Epilepsy - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Epilepsy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.
To access full report with TOC, please visit Epilepsy - Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Epilepsy
- The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects
- The report assesses Epilepsy therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Epilepsy
- The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects
- The report assesses Epilepsy therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Epilepsy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Epilepsy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Epilepsy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Adamas Pharmaceuticals, Inc. Advicenne Aeolus Pharmaceuticals, Inc. Aequus Pharmaceuticals Inc. Aestus Therapeutics, Inc. Alexza Pharmaceuticals, Inc. Anavex Life Sciences Corp. Asklepios BioPharmaceutical, Inc. Astellas Pharma Inc. Bial - Portela & Ca, S.A. BioCrea GmbH Biogen Inc Bionomics Limited Biovista Inc. Biscayne Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc. D-Pharm Ltd. Eisai Co., Ltd. Glialogix, Inc. Grifols, S.A. GW Pharmaceuticals Plc H. Lundbeck A/S Hyundai Pharmaceutical Co., Ltd. INSYS Therapeutics, Inc. INVENT Pharmaceuticals, Inc. Iproteos S.L. Johnson & Johnson Knopp Biosciences LLC Lead Discovery Center GmbH Lipicard Technologies Limited Lotus Pharmaceutical Co., Ltd. Marathon Pharmaceuticals, LLC Marinus Pharmaceuticals, Inc. Mitochon Pharmaceuticals, Inc. Neurelis, Inc. Neurocrine Biosciences, Inc. Neuron Biopharma SA Novartis AG OPKO Health, Inc. Ovid Therapeutics Inc. Pfizer Inc. PharmatrophiX, Inc. Promius Pharma, LLC PTC Therapeutics, Inc. Retrophin Inc. Sage Therapeutics, Inc. Saniona AB SciFluor Life Sciences, LLC Shire Plc SK Biopharmaceuticals Co., Ltd. Suda Ltd Sumitomo Dainippon Pharma Co., Ltd. Takeda Pharmaceutical Company Limited Trillium Therapeutics Inc. Turing Pharmaceuticals AG UCB S.A. Ultragenyx Pharmaceutical Inc. Upsher-Smith Laboratories, Inc. Vichem Chemie Research Ltd. VistaGen Therapeutics , Inc. Vitality Biopharma Inc Xenon Pharmaceuticals Inc. XERIS Pharmaceuticals, Inc. Zogenix, Inc. Zynerba Pharmaceuticals, Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
No comments:
Post a Comment